Novavax (NVAX) volatility elevated into Phase III RSV vaccine data

August 8, 2016 1:44 PM EDT

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Novavax (NASDAQ: NVAX) August call option implied volatility is at 102, September is at 159; compared to its 52-week range of 61 to 140 into the expected release of Q2 results on August 9 and Phase III RSV vaccine data in Q3.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Options, Trader Talk

Related Entities


Add Your Comment